Instruments

Name Stock exchange Average volume Price Type
JB/CALL/BMW/115/0.0666/21.06.24 BMYKJB

Berne S.E.

- - CHF Warrant JB/CALL/BMW/115/0.0666/21.06.24 Warrant

News (67)

Notice to the Annual General Meeting 2024 in Crown Energy AB (publ) AQ
Announcement from Crown Energy's Annual General Meeting AQ
Notice to the Annual General Meeting 2023 in Crown Energy AB (publ) AQ
Novocure Announces Organizational Changes to Prepare for Future Growth BU
Novocure Announces Executive Changes CI
Novocure to Participate in Upcoming Investor Conferences BU
Announcement from Crown Energy's annual general meeting AQ
Transcript : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer BU
Novocure : Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer - Form 8-K PU
Transcript : NovoCure Limited, Q4 2021 Earnings Call, Feb 24, 2022
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting BU
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma BU
Novocure : Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting BU
Crown Energy : Announcement from Crown Energy’s annual general meeting PU
Crown Energy : Announcement from Crown Energy's annual general meeting AQ
Crown Energy : Notice to the Annual General Meeting 2021 in Crown Energy AB (publ) AQ
Transcript : NovoCure Limited, Q4 2020 Earnings Call, Feb 25, 2021
NovoCure : First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma BU
Novocure : Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting BU
Transcript : NovoCure Limited - Shareholder/Analyst Call
Novocure : Announces Agenda for Virtual Research and Development Day BU
Transcript : NovoCure Limited, Q3 2020 Earnings Call, Oct 29, 2020
Transcript : NovoCure Limited, Q2 2020 Earnings Call, Jul 30, 2020
Crown Energy : Announcement from Crown Energy’s annual general meeting PU
Crown Energy : Announcement from Crown Energy's annual general meeting AQ
Crown Energy : Notice to the Annual General Meeting 2020 in Crown Energy AB (publ) AQ
Transcript : NovoCure Limited, Q1 2020 Earnings Call, Apr 30, 2020
Crown Energy : Notice to the Annual General Meeting 2020 in Crown Energy AB (publ) AQ
Transcript : NovoCure Limited, Q4 2019 Earnings Call, Feb 27, 2020
Transcript : NovoCure Limited, Q3 2019 Earnings Call, Oct 31, 2019
Novocure : Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting BU
Transcript : NovoCure Limited, Q2 2019 Earnings Call, Jul 25, 2019
Transcript : NovoCure Limited, Q1 2019 Earnings Call, May 02, 2019
Novocure :’s Chief Science Officer Retires after 17 Years of Service BU
Novocure Announces Executive Changes CI
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients GL
Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium GL
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium GL
Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer GL
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage GL
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting GL
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting GL
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress GL
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress GL
12NextSee all

Companies (25)

ELI LILLY AND COMPANY 727 B $
Logo Eli Lilly and Company

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunolog ...

SHISEIDO COMPANY, LIMITED 12 682 M $
Logo Shiseido Company, Limited

Shiseido Company, Limited specializes in the design, manufacturing and marketing of cosmetics. The group offers beauty products (including makeup items, coloring, etc. ; Shiseido, Aupr's, DQ, Za, Revital Granas, B?n?fique, Maquillage and Elixir), skin car ...

ELIS 5 856 M $
Logo Elis

Elis figures among the European leaders in services of rental and maintenance of table and household linen, work clothes and hygiene and wellness equipment. The services are provided to more than 400,000 companies operating in the hotel and restaurant tra ...

ELICIO THERAPEUTICS, INC. 82 M $
Logo Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics direct ...

POWR LITHIUM CORP. 3 M $
Logo POWR Lithium Corp.

POWR Lithium Corp. is a Canada-based mineral exploration and development company. The Company is focused on American lithium deposits. The Company holds interests on the Halo and Eli properties in Nevada. The Company is also focusing on the development of ...

BIOPHARM - $
Logo BIOPHARM

Biopharm SPA is one of the leading pharmaceutical groups in Algeria. The group manufactures generic pharmaceuticals under its own brands, as well as licensed drugs for laboratories such as Sanofi, Eli Lilly and Pierre Fabre. At the end of 2022, Biopharm ...

DAR GLOBAL PLC 671 M $
Logo Dar Global PLC

Dar Global PLC is a United Kingdom-based company engaged in a differentiated international real estate business. The Company focuses predominantly on developing real estate projects comprising second homes for internationally mobile customers in locations ...

PRIME DRINK GROUP CORP. 17 M $
Logo Prime Drink Group Corp.

Prime Drink Group Corp. is engaged in acquiring spring water permits to develop operations in the spring water market in Quebec. The Company seeks to acquire and integrate beverage businesses in diversified sectors. The Company’s water rights comprise D ...

FREMONT GOLD LTD. 3 M $
Logo Fremont Gold Ltd.

Fremont Gold Ltd. is a Canada-based gold company. The principal business activity of the Company is the acquisition and exploration of mineral properties located in the United States. The Company's projects include Griffon gold project (Griffon), Cobb Cre ...

ARAB PALESTINIAN INVESTMENT COMPANY 306 M $
Logo Arab Palestinian Investment Company

Arab Palestinian Investment Company, Ltd. (APIC) is a Jordan-based company that is engaged in the investment activities in the Palestinian market businesses. APIC, along with its subsidiaries and associated companies, is involved in the manufacturing, dis ...


123Next

Insiders

Picture Ely Benaim
Ely Benaim

Ely Benaim is Chief Medical Officer at NovoCure Ltd. In the past Dr. Benaim occupied the position of Vice President-Clinical Affairs at Sangamo Therapeutics, Inc., Chief Medical Officer & SVP-Regulatory Affairs at Berg Pharma LLC, Senior Director-Clinical Research at Millennium Pharmaceuticals, Inc., Chief Medical Officer of Rexahn Pharmaceuticals, Inc., Senior Director-Global Oncology at Salmedix, Inc. and Assistant Professor at the University of Tennessee. Dr. Benaim received a doctorate from Central University of Venezuela.


Picture Raphael Michael Benaim
Raphael Michael Benaim

Raphael Michael Benaim is currently the Director at Harrow Holdings Ltd.
and the Chief Investment Officer & Managing Partner at Destra Investment Advisory LLP.
Previously, he worked as a Partner at Shooter Fund Management LLP in 2007.





Picture Deborah Benaim
Deborah Benaim

Deborah Benaim worked as a Managing Director in the Structured Settlement Division at Peach Holdings, Inc. She was also a Director at the American Seniors Housing Association.
Prior to that, she was a Senior Vice President at Grand Court Lifestyles, Inc. and later became a Senior Vice President at Emergent Capital, Inc. She also worked as a Vice President at Settlement Funding LLC and at Prudential Bache Securities, Inc. Ms. Benaim's former job(s) include Managing Director, Director, Senior Vice President, and Vice President.





No results for this search